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Abstract
The distribution of 6/3 integrin in adhesion com-
plexes at the basal membrane in human normal and
cancer prostate glands was analyzed in 135 biopsies
from 61 patients. The levels of the polarized 6/3
integrin expression at the basal membrane of prostate
tumor glands were determined by quantitative immuno-
histochemistry. The 6/3 integrin expression was
compared with Gleason sum score, pathological stage,
and preoperative serum prostate -specific antigen
(PSA). The associations were assessed by statistical
methods. Eighty percent of the tumors expressed the 6
or 3 integrin and 20% was integrin-negative. Gleason
sum score, but not serum PSA, was associated with the
integrin expression. Low Gleason sum score correlated
with increased integrin expression, high Gleason sum
score with low and negative integrin expression. Three
prostate tumor phenotypes were distinguished based
on differential integrin expression. Type I coexpressed
both 6 and 3 subunits, type II exclusively expressed
6 integrin, and type III expressed 3 integrin only.
Fifteen cases were further examined for the codistribu-
tion of vinculin, paxillin, and CD 151 on frozen serial
sections using confocal laser scanning microscopy.
The 6/3 integrins, CD151, paxillin, and vinculin were
present within normal glands. In prostate carcinoma, 6
integrin was colocalized with CD 151, but not with
vinculin or paxillin. In tumor phenotype I, the 6 subunit
did not colocalize with the 3 subunit indicating the
existence of two different adhesion complexes. Human
prostate tumors display on their cell surface the 61
and/or 31 integrins. Three tumor phenotypes asso-
ciated with two different adhesion complexes were
identified, suggesting a reorganization of cell adhesion
structures in prostate cancer.
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Introduction
Prostate carcinoma is the most commonly diagnosed visceral
neoplasm in men and has become one of the nation’s major
health problems. However, its basic biology is still not well
understood [1].
A great biological variability in the rate of clinical
progression is seen in prostate cancer patients. In addition,
in most men afflicted with prostate cancer, there are multiple
tumors showing variations in the morphologic pattern. DNA
analysis and in situ hybridization studies showed that multiple
tumors from the same prostate were genetically different and
smaller tumors may give rise to distant lymph node meta-
stasis [2,3 ]. The hypothesis of the independent origin of
multiple tumors in prostate cancer was also supported by the
demonstration of discordant allelic deletion patterns on
chromosomes 8p12-21 and 17q21 in distinctly separate
tumors [3-5].
A hallmark feature in all prostate cancers is the pro-
gressive loss of basal cells that are attached to the underlying
extracellular matrix (ECM) in normal glands by two major
junctional structures, the hemidesmosomes (HDs) and focal
adhesions (FAs) [6,7 ]. In neoplastic prostate cells, the
formation of HDs and the expression of their components
including laminin 5 [6,7 ], which is the extracellular ligand of
the 64 integrin complex in HDs [8,9], are not observed.
Thus, neoplastic cells do not express 4 integrin, a hemi-
desmosomal protein, at the basal membrane. Although
integrins are downregulated in most human carcinoma,
invasive prostate carcinoma shows a persistent expression
of 3 and 6 integrins [10].
In human skin, mutations in both alleles of either 6 or
4 integrins cause an inherited recessive blistering disorder
called junctional epidermolysis bullosa associated with
pyloric atresia (PA-JEB) [11,12]. In cultured keratinocytes
from a patient exhibiting a complete absence of the 4
integrin subunit, the 6 integrin subunit lacking its 4 partner
formed a complex with the 1 subunit and redistributed with
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vinculin to FAs [12], whereas in normal human keratino-
cytes, the 31 complex generally is recruited to FAs and the
64 integrins to HDs [13]. Both 6 and 4 null–mutant
mice lacking HDs showed a widespread subepidermal
blistering [14-16]. Both 3-null and 6-null mutations were
shown to be lethal [17], whereas heterozygote 3± /6±
mice showed multiple defects in organ development includ-
ing the urogenital tract revealing synergistic activities for
these integrins during murine embryo development [16].
These observations indicate that the 64 and 31
integrins play an essential role in cell adhesion.
In addition, the adhesion structures in skin contain the
tetraspan TM4 protein designated CD151. CD 151 forms
complexes with the 31 or 64 laminin-binding inte-
grins and colocalizes with 64 in HDs in human skin
[18]. HDs and FAs were shown to be dynamic and to
change their molecular composition during their maturation
[18–21].
Cell adhesion plays a crucial role in migration and
invasion of malignant cells to distant tissues. It is suspected
that the integrin expression is related to the invasive and
migratory potential of tumors [22–26]. Because prostate
carcinoma shows a persistent expression of 6 and 3
integrins, we therefore examined the relationship of Gleason
sum score, pathological stage, and preoperative serum
prostate-specific antigen (PSA) with the 6 and 3 integrin
expression. In this study, we observed three different
prostate tumor phenotypes reflecting different adhesion
structures in prostate cancer.
Materials and Methods
Clinical Material
For this study, 135 biopsy cores containing prostate
carcinoma were analyzed from 61men seen at the University
of Arizona Health Sciences Center between 1993 and 1999.
These biopsies were collected with IRB approval (Assurance
of Compliance no. M-1233). Men with a suspicious nodule
on digital rectal examination or serum PSA levels greater
than 4 ng/dl were biopsied transrectally under ultrasound
guidance using a Biopty gun with an 18-gauge spring loaded
Trucut needle (Biopty, Bard Urological Division, Covington,
GA). Sextant samples were typically obtained from the apex,
midbase, and peripheral zones bilaterally. Immediately
following biopsy, the tissue cores were oriented apex- to-
base flat in the bottom of a metal embedding mold. The mold
was carefully filled with OCT compound embedding media
(Miles, Diagnostic Division, Elkhart, IN) and snap- frozen by
immersion in a Freon cooled bath of isopentane using a
Lipshaw Shandon Histobath (Detroit, MI). The tissues were
stored at 808C.
In this study, 56 men underwent subsequent radical
retropubic prostatectomy (RRP). Five men elected not to
have surgery. The removed prostates were totally embedded
and used to accurately record Gleason sum scores [27] as
well as pathologic stage. Serum PSA was presurgically
obtained and at 6-month intervals following RRP and was
used to assess chemical recurrence. Two men died — one
due to disseminated coccidiomycosis, and another one of his
disseminated disease. Four men were lost to follow-up. Of
the remaining 55 men, 7 men (8%) developed evidence of
residual disease with return of positive serum PSA greater
than 0.02 ng/dl.
Immunohistochemistry
Samples of frozen biopsies were serially sectioned (3–
4 m) with a cryostat. Serial sections were picked up on
sequentially labeled, charged glass slides. For diagnosis
and grading of the carcinoma lesions, sections of all 135
biopsies were stained with hematoxylin /eosin (H&E), and
reacted with antibodies against cytokeratins 5 and 14
specific for basal cells, and with antibodies specific for 6,
3, and 4 integrins. For immunoperoxidase staining,
frozen sections were fixed for 5 minutes in 208C cold
acetone, incubated in primary antibody diluted in PBS
containing 1% BSA for 30 minutes at room temperature,
and rinsed in three changes of PBS. Biotinylated secondary
antibodies to mouse and rabbit were localized with biotin–
streptavidin conjugated to horseradish peroxidase (LSAB 2
kit; Dako, Carpinteria, CA). The final color reaction was
developed in diaminobenzidine substrate. Tissue sections
were counterstained with hematoxylin.
Immunohistochemical Quantitation
H&E–stained sections of each biopsy core were
examined for the presence of tumor and graded using
the Gleason sum score system. Additional sequential
sections were immunolabeled with antibodies specific for
3, 6, and 4 integrins and visualized by streptavidin–
biotin DAB (Dako). Two observers using a double-headed
scope viewed the H&E–stained sections together in order
to agree on the areas of cancer. Then the scoring of the
intensity of the integrin staining in each tumor was done
separately by these two observers. Only integrin immunos-
taining polarized at the interface with the ECM of the
carcinoma cells was considered positive. Diffuse cytoplas-
mic integrin staining was not scored. The 6, 3, and 4
integrin stainings were scored separately from each other.
Thus, each biopsy obtained three scores. The immunostain-
ing intensity was scored as follows: 1=negative; 2=weak;
3=strong. The percentage of cancerous glands within each
biopsy section showing clustering of the 6/3 integrin
subunits at the basal membranes per tumor was scored as
follows: 1=0% to 25%; 2=25% to 50%; 3=50% to 75%; and
4=75% to 100%. The final score of the staining in each
biopsy was determined by multiplying the intensity score
times the estimated percentage of the cancerous glands
stained. Thus, a biopsy without polarized integrin staining at
the interface to the ECM in cancerous glands would receive a
final score of 11=1. A biopsy showing strong polarized
immunostaining at the interface to the ECM ( intensity score
3) in 75% to 100% of the cancerous glands (percentage
score 4) would obtain a final score of 34=12. The ‘‘within-
patient variability,’’ which was not measured specifically, was
taken into account by the percentage of glands showing this
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special integrin staining pattern. The combined score
reflected both the intensity of staining and the extent of
staining.
Confocal Laser Scanning Microscopy
For immunofluorescence microscopy, 15 selected frozen
biopsies from 5 patients were serial sectioned with a
cryostat, mounted on glass slides, fixed in 208C acetone
for 10 minutes, and then briefly air -dried. Primary anti-
bodies were directly applied for 30 minutes, followed by
three 5-minute washes in PBS. Secondary antibodies were
incubated for 30 minutes, and then rinsed off with three
5-minute washes in PBS. Prior to mounting, the sections
were rinsed in water, and then postfixed in 100% ethanol for
3 minutes.
Immunofluorescence was observed with a confocal laser
scanning immunofluorescence microscope (LSM 410; Carl
Zeiss, Jena, Germany). For simultaneous double- label
fluorescence, an argon/krypton ion laser operating at 488
and 568 nm was used, together with a long-pass filter of 590
for visualization of Alexa 568 fluorescence and a band-pass
filter of 515 to 540 for visualization of Alexa 488 fluores-
cence, respectively. RGB images were taken in high-
resolution mode using 10241024 image points (pixels)
and 8-second scan time. Noise levels were reduced by line
averaging of the scans.
Antibodies
Mouse monoclonal antibodies against cytokeratins 5 and
14 (clones KA1 and KA2) were generated and characterized
according to standard protocols [28]. The following murine
monoclonal antibodies were purchased: alpha 3 integrin
clone P1B5 and beta 4 integrin clone 3E1 (Gibco BRL Life
Technologies, Rockville, MD), CD 151 clone 14A2.H1
(Research Diagnostics, Flanders, NJ), vinculin clone 11-5
(Sigma, St. Louis, MO), paxillin clone 349 (Transduction
Laboratories, Lexington, KY), and laminin 5 clone GB3
(Sera-Lab, Sussex, England, UK). Mouse monoclonal
antibody 4C7 specific for the laminin 5 chain ( laminin 10)
Figure 1. Immunoperoxidase localization of 4, 3, and 6 integrins in normal
and malignant prostate glands. Frozen serial sections of prostate tissue
containing normal glands (N ) and Gleason sum score ( 3+3=6 ) infiltrating
carcinoma were stained with H&E (A ) or immunoreacted with specific
antibodies to 4 (B ), 3 (C ), or 6 (D ) integrins as indicated. All three
integrins were expressed in the epithelial basal membrane in the normal
glands. Some weak staining with anti -4 integrin antibody was detected
within the malignant epithelial cytoplasm, but none in the basal membrane of
malignant epithelia. Note 4 expression in periglandular vascular basement
membranes. Both antibodies specific for 3 and 6 integrins focally outlined
the basal membranes (arrows ) of malignant glands. Arrowheads: blood
vessels; N: normal glands. Bar, 20 m.
Figure 2. Expression profile of 6 and 3 integrins polarized at the basal
membranes of human prostate carcinoma epithelium. One hundred and
thirty - five needle biopsy containing carcinoma obtained from 61 patients were
analysed for the expression of the 6 and /or 3 integrin subunit and the
intensity of the immunoreaction was scored: 2 to 12=all expression; 2 to
8= low expression; 9 to 12=high expression. Graph (A ) demonstrates the
percentage of all biopsies analyzed (135=100%) that expressed 6 and /or
3 integrin. The group of cases with the expression levels 2 to 12 included the
cases with high expression levels 9 to 12, which also were analyzed
separately (A ). Graph (B ) shows the expression profile of the integrin
subunits in association with the tumor grading (Gleason sum score ). The
definitions of the descriptors are: 6, all cases which expressed 6 integrin;
3, all cases which expressed 3 integrin; integrin -negative, all cases which
were integrin -negative. None of the tumors expressed polarized 4 integrin.
The Gleason sum score was found to be inversely associated with the integrin
expression.
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was kindly provided by Dr. Eva Engvall (The Burnham
Institute, La Jolla, CA) [29]. The rat monoclonal antibody
specific for alpha 6 integrin clone J1B5 was generously
provided by Dr. Caroline Damsky (University of California,
San Francisco, CA) [30].
Secondary antibodies used were Alexa Fluor 488 goat
antimouse IgG and Alexa Fluor 568 goat antimouse or antirat
IgG (Molecular Probes, Eugene, OR).
To reduce background and nonspecific reaction, the
monoclonal antibody (clone J1B5) specific for alpha 6
integrin was purified as follows: 100 ml of JIB5 conditioned
medium was loaded onto a 5-ml Hi -Trap protein G
Sepharose column (Amersham Pharmacia Biotech, Piscat-
away, NJ). The column was washed with three column
volumes of 100 mM Tris /HCl (pH 7.9) and three column
volumes of 10 mM Tris /HCl (pH 7.9) followed by washing
with two column volumes of 100 mM glycine (pH 3.7). JIB5
was eluted with 15 column volumes of 100 mM glycine (pH
2.8). The pH of the eluate was readjusted to pH 7.9 by
adding 50 l of 1 M Tris /HCl (pH 8.5) /ml eluate.
Statistical Method
An estimation of the intraclass correlation coefficient,





of between-patient variability and Se
2 is within-patient
variability, was used to explore the intrapatient variability
for measurement of Gleason sum score, 3, 6, or 3+6
integrins. Because the Gleason sum scores were correlated
with each patient, the Generalized Estimating Equations
(GEE) model was used to analyze the association between
Gleason score and 3, 6, 3+6 integrins [31]. For the
association between preoperative serum PSA and 3, 6,
3+6 integrins, the Spearman rank-order correlation was
used [32]. The difference in expression between the
phenotypes was evaluated by the Kruskal -Wallis test [33].
Results
For this study, 135 biopsy cores containing prostate
carcinoma from 61 men were analyzed for the polarized
expression of 6, 3, and 4 integrins at the basal
membrane of malignant prostate epithelium. The expres-
sion level concentrated at the basal membrane was scored
(1–12; 1=negative, 2=low, 12=high). In prostate carci-
noma, both a diffuse surface pattern and a clustering of 6
and 3 integrins at the basal membrane were observed
(Figure 1;C and D ). The 6 and 4 integrins were also
positive in blood vessels (Figure 1;B and D ). Consistent
with our previous results [10], the polarization of 4
integrin at the basal membrane was not detected in any
prostate tumor gland in which 6 and/or 3 integrins were
clustered at the basal membrane (Figure 1B ). Laminin 5,
the extracellular ligand of the 64 integrin complex, was
also found to be absent in these glands (data not shown).
The Expression Levels of 6/3 Integrins and Association
with Gleason Sum Score and PSA Levels
The patients’ preoperative PSA levels, Gleason sum
score, and pathological stage of each tumor at the time of
prostatectomy were recorded and compared to the integrin
staining pattern.
Analysis of serial sections by immunohistochemistry
revealed that 80% of the tumors examined expressed either
6 or 3 integrin (Figure 2A ). A total of 70% of the tumors
expressed 6 integrin and 54% expressed 3 integrin within
a range from low to high expression levels (2–12). Within
the group of tumor glands showing high expression levels
(9–12) at the basal membrane (Figure 2A ), 37% highly
expressed either 6 or 3 integrin, 34% showed high levels
of 6 integrin, 10% showed high levels of 3 integrin.
Approximately 20% of the tumors examined showed no
expression of either 6 or 3 integrin at the basal membrane.
Interestingly, three different phenotypes of prostate
tumors were observed: 1) 44% of the tumors coexpressed
both 6 and 3 subunits ( type I ), with 4.4% showing high-
level expression (9–12) of both subunits (Figure 2A ); 2)
26% of the tumors exclusively expressed the 6 subunit
Table 1. Association between Integrin Expression and the Three Tumor
Phenotypes.
(A ) The Median of Expression Level for Each Tumor Phenotype
Median
3 integrin only 2
6 integrin only 8
3+6 12
(B ) The Statistical Significance (P Value ) of Difference
3 only versus 6 only 3 only versus 3+6 6 only versus 3+6
.0012 .0003 .0003
Table 2. Association between Gleason Sum Score and 6, 3, 6, and 3
Integrin Expression.
(A ) The Intraclass Correlation Coefficient for Gleason, 6, 3, 6+3
Integrin
Gleason 6 3 6+3
Within - patient variability: S e
2 0.4986 6.9700 3.5033 11.8756
Between -patient variability: S T
2 1.1092 12.4917 4.5184 21.5735
Intraclass correlation coefficient: R 0.6986 0.6418 0.5633 0.6449
(B ) The Statistical Significance for the Association between Gleason Sum
Score and 6, 3, 6+3 Integrin
6 3 6+3
Gleason sum score (P values ) .0272 .0001 .0001
Table 3. The Association between Serum PSA and 6, 3, 6, and 3
Expression.
The Spearman Rank -order Correlation Between PSA and 6, 3, 6+3
Expression
6 3 6+3
Correlation 0.0108 0.06831 0.0452
P value for correlation .9373 .6169 .7429
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alone ( type II ), with 12.5% showing high expression levels
(9–12) of 6 integrin only (Figure 2A ); and 3) 10% of the
tumors exclusively expressed the 3 subunit ( type III ) at the
interface of the cell–ECM site (Figure 2A ), with only a few
tumors (0.74%; Figure 2A ) expressing high levels (9–12) of
the 3 subunit without expressing the 6 subunit. Because
the expression values were not normally distributed, the
Kruskal -Wallis test was performed to test the difference
among the three tumor phenotypes. The differences for
these three tumor phenotypes were statistically significant
(see Table 1).
Whether the group of integrin-negative tumors represent
a fourth phenotype or is a result of poor preservation will
require further examination. Because these specimens were
snap- frozen immediately after biopsy, it is likely that these
are truly integrin-negative.
The biopsies then were arranged into two groups
according to the Gleason sum score (6, 7) and the
integrin expression profile analyzed for these two groups
(Figure 2B ). Within the group of tumors with Gleason sum
score 6, a total of 83% expressed 6 integrin, and 66%
expressed 3 integrin (Figure 2B ). Neither of the two
subunits was expressed in 5% of tumors in this group. From
the tumors with Gleason sum score 7, a total of 29% of the
tumors expressed 6 integrin, 27% expressed 3 integrin,
and 54% showed no expression at all of either subunit at the
basal membrane (Figure 2B ). We questioned whether
there was an association between Gleason sum score and
Figure 3. Distribution pattern of tumor phenotypes as compared to Gleason sum score (A ) and pathological stage (B ). (A ) The distribution pattern of the three
phenotypes in relation to the Gleason sum score. A total number of 94 biopsies (100%) were graded with Gleason sum score 6, and 41 biopsies ( 100%) with
Gleason sum score7. (B ) The distribution of the three phenotypes in relation to the pathological staging within the biopsy group with Gleason sum score6. Of the
135 biopsies examined, 94 were graded with Gleason sum score 6 and were correlated after prostatectomy to pathological staging as follows: T1a to T2c=29
biopsies; T3a to T3b=38 biopsies; and T3c=27 biopsies. (C ) The average expression intensity ( 2–12 ) of the individual integrin subunits in each phenotype
compared to the pathological stage and Gleason sum score 6. (D ) The distribution of the three phenotypes in relation to the pathological stage T3a to T3b within
the biopsy group (26 biopsies ) with Gleason sum score 7 ( for pathological stages T1a to T2c and T3c, the number of cases available for examination was too low
to be representative ).
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PSA with 6, 3, or 6+3 integrin expression. The
estimation of the intraclass correlation coefficient was
computed for the Gleason sum score, 6, 3, and 6+3
(Table 2A). This test also included the group of integrin
negative biopsies. The Gleason sum score was inversely
associated with the 6 integrin expression (P value .0272;
Table 2B). Low Gleason sum scores were significantly
related to increased 6 expression levels at the basal
membrane (Figure 2B ). Likewise, the Gleason sum score
and 3 integrin expression (P value .0001), and the
Gleason sum score and both 6+3 integrin expression
(P value .0001) were inversely associated (Table 2B),
Figure 2B ). There was also a significant correlation
between Gleason sum score and the group of integrin -
negative biopsies (Figure 2B ). These integrin-negative
biopsies were predominantly seen in the group of less well -
differentiated samples, with high Gleason sum scores
suggesting that in these cases a nonintegrin adhesion
receptor may be involved in cell–substrate attachment.
No association between serum PSA (Table 3) and 6,
3, 6, and 3 integrin expression was observed.
The correlation between disease- free survival rate in
patients with any of the three phenotypes could not be tested
because no significant association between disease- free
survival rate in patients and pathological stage or Gleason
sum score was found in this study.
The Correlation of Phenotypes with Gleason Sum Score
and Pathological Stage
The distribution of the three prostate tumor phenotypes
in relation to the Gleason sum score was observed as
follows: for Gleason sum score 6, 55% coexpressed both
6+3 integrin ( type I ), 29% of the tumors in this group
expressed 6 integrin only ( type II ), whereas only 6.3%
exclusively expressed 3 integrin ( type III; Figure 3A ). For
Gleason sum score 7, 17% coexpressed both subunits
( type I ), 17% expressed 6 integrin only ( type II ), whereas
10% expressed 3 integrin only ( type III; Figure 3A ). Taken
together, these data suggest that increasing Gleason sum
score selects against the predominance of a type I adhesion
phenotype. Interestingly, 44% of the prostate tumors graded
with Gleason sum score 7 and higher, which is correlated
with decreased differentiation, was equally likely to express
either phenotype I, II, or III (Figure 3A ).
A subset of tumors graded with Gleason sum score 6
(94 biopsies) was analyzed for the expression pattern of the
different phenotypes in relation to pathological staging. For
stage T1a–T2c, 48% coexpressed 6 and 3 integrins, 28%
expressed 6 integrin only, and 10% expressed 3 integrin
only (Figure 3B ). For stage T3a–T3b, 63% coexpressed 6
and 3 integrins, 21% expressed 6 only, and 15%
expressed 3 integrin only (Figure 3B ). For stage T3c,
52% coexpressed both 6 and 3 integrin, 41% expressed
Figure 4. Confocal laser scanning micrographs of double - label immunofluorescence microscopy of 6 integrin (B, C, E, F; green ) with vinculin (A, C; red ) and
paxillin (D, F; red ) in human normal prostate glands. Overlays are shown in (C ) and (F ). Note that in most of the areas, the red was resolved from the green. A few
areas showed yellow indicating some colocalization of the 6 integrin with either vinculin or paxillin. Note that vinculin is also present in smooth muscle cells. Bars, 10
m (A ), 2 m (D).
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6 integrin only, and none expressed 3 integrin only
(Figure 3B ).
In the subset of tumors (41 biopsies) graded with Gleason
sum score 7, the pathological stages were unevenly
Figure 5. Confocal laser scanning micrographs of simultaneous detection of 6 integrin (A, D, G, J; red ) and cytokeratins 5 and 14 (B; green ), paxillin (E; green ) or
vinculin (H, K; green ) in the malignant prostate epithelium of two patients ( patient 1: Gleason grade 3+3, pathological stage T3c, shown in A–C; patient 2: Gleason
grade 3+3, pathological stage T3c, shown in D–L ). Overlays are shown in (C, F, I, L ). Malignant glands were distinguished from normal glands by the absence of
cytokeratins 5 and 14 (A–C). Note the abundant staining of the basal membrane in normal glands, whereas the basal membranes in malignant glands were outlined
by an attenuated staining. In serial sections (D– I ), the distribution of 6 was compared to paxillin (D–F ) and vinculin (G–L ). The field within the white frame in ( I ) is
shown at high magnification in ( J –L ), revealing that 6 was not distributed to focal adhesions in malignant prostate glands lacking the 4 integrin subunit. Both
paxillin and vinculin strongly stained smooth muscle cells. Vinculin was also expressed in the apical junctional zone of the luminal cells ( arrows ). N, normal gland; C,
cancer; C1, cancer gland 1 indicating the same gland in two serial sections; L, lumen of gland. Bars, 10 m (B ), 5 m (E, F ), 2 m (K).
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represented. For example, only two biopsies with stage
T1a–T2c were available for the examination of the integrin
expression; of these, one case expressed the 6 integrin
only ( type II ), and the other was integrin-negative. For
pathological stage T3c, eight biopsies were available. Of
these, two tumors still expressed 6 integrin only ( type II ),
one tumor expressed 3 only ( type III ), and the expression
of 6+3 integrin ( type I ) was not observed. In stage T3a–
T3b (26 biopsies; Figure 3D ), 22% expressed 6+3
integrin ( type I ), 19% expressed 6 integrin only ( type II ),
and 11% expressed 3 integrin only ( type III ). Five biopsies
were not staged because prostatectomy was not performed.
Overall, these data indicate that in higher pathological
stages, a selection for the expression of 6 integrin adhesion
may occur and that the phenotype III (3 integrin only) may
be suppressed.
When analyzing the average expression intensities of
the integrin subunits in each phenotype (Figure 3C ), it
appeared that 6 integrin showed the highest intensity
levels compared with the 3 integrin expression. Within the
phenotype I, the average 6 and 3 expression levels
were similar in the pathological stage T1a–T2c, whereas in
stages T3–T3b and T3c, the expression intensities for the
6 subunit were two- fold higher than for the 3 subunit
(Figure 3C ).
Immunofluorescence Localization of 6 and 3 Integrins in
Normal and Neoplastic Prostate Glands
In normal prostate glands, the majority of the 6 integrin
subunits pair with the 4 subunit, consistent with the
formation of a hemidesmosomal structure. A minor amount
of the 6 integrin subunit pairs with 1 integrin. The 61
integrin in cell cultures is associated with FAs containing, in
part, vinculin and paxillin [34]. In prostate cancer however,
the 4 integrin subunit and the majority of other integrin
subunits (with the exception of 1, 6, and 3) are no longer
observed on the tumor cell surfaces [10]. The assembly of
alpha–beta integrin complexes is required for the transport
through the Golgi apparatus to the plasmamembrane and for
the exposure of integrin subunits on the cell surface [35]. In
prostate tumor cells consequently, the 6 and the 3
subunits have to be expressed on the cell surface in a
complex with the 1 subunit. To determine the 6 integrin
location with respect to FAs in prostate cancer, we perfor-
med a double-staining immunofluorescence comparison of
6 integrin with vinculin and paxillin in frozen sections of
normal and neoplastic prostate (Figures 4 and 5 ). In the
normal prostate gland, 6 integrin, vinculin, and paxillin
were intensely expressed at the basal membrane
(Figure 4 ). The 6 integrin staining overlapped in some
areas with both the vinculin and paxillin staining (Figure
4;C and F ). In other areas, the 6 integrin staining could
be resolved from the vinculin or paxillin staining (Figure
4;C and F ), reflecting that they did not colocalize. These
data indicated heterogeneity of these adhesion complexes
in the normal prostate gland. Vinculin, which is also known
to contribute to E-cadherin containing cell–cell junctions in
certain cell types, was expressed in the apical junctional
region of the Luminal cells in normal glands (not shown).
In addition to glands, vinculin and paxillin were also
prominently expressed in the surrounding smooth muscle
cells (Figures 4A and 5;E and H ). The 6- integrin was
found to be strongly expressed in blood vessels (Figures
1D and 7;A and E ).
In prostate cancer, the hemidesmosomal structures
(HDs) and the clustered expression of hemidesmosomal
proteins, especially the 4 integrin, are not observed. We
questioned whether 6 integrin would colocalize with vinculin
or paxillin to FAs in the absence of its HD partner 4 integrin
in malignant prostate glands. For identification of cancerous
and normal glands, sections were first analyzed by detecting
simultaneously the 6 subunit and cytokeratins 5 and 14
(Figure 4;A C ). In normal cytokeratin 5– and 14–positive
glands (Figure 5;A C ), the 6 integrin staining of the basal
membrane appeared as a strong wide band (Figure
5;A;D;G ), whereas in the cytokeratin 5– and 14–negative
cancer glands, the 6 integrin staining appeared less
intensely in a fine line (Figure 5A ). Sections then were
processed for simultaneous detection of 6 integrin and
either paxillin (Figure 5;D  F ) or vinculin (Figure 5;G  L ).
Both paxillin and vinculin were abundantly expressed in the
smooth muscle cells, and less intensely at the glandular
basal membranes. In addition, vinculin was also expressed
in the apical junctional region of the luminal cells in the
neoplastic glands (Figure 5;H ; I;K ; L ). In the absence of the
4 integrin subunit, we were surprised to discover that the 6
integrin did not colocalize with either paxillin (Figure
5;D  F ) or vinculin (Figure 5; J  L ) in the FAs of the
Figure 6. Simultaneous detection of 6 integrin ( red ) with CD151 (green ) in
human malignant prostate glands (Gleason grade 3+3, pathological stage
T3c ) as viewed by indirect immunofluorescence and laser scanning confocal
microscopy. CD151 (A, B, D: green ) and 6 integrin (A, B, C: red ) colocalized
( yellow ) at the interface of epithelium to basal membrane. (A ) Shows field of
malignant prostate glands. Malignant gland 1 is shown at higher magnification
in (B–D). N, normal gland. Bars, 10 m (A ), 5 m (B ).
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malignant prostate glands. To determine whether 6 integrin
colocalized with the tetraspan molecule CD151 in these
malignant glands, we performed a double staining with
antibodies specific for these two antigens. As shown in
Figure 6;A D ), 6 integrin colocalized with CD151 at the
basal membranes of the malignant glands in most areas. CD
151 was also present in the basal membrane of normal
prostate glands (Figure 6A ). In addition, CD 151 was
observed on the surface of epithelial cells in normal and
neoplastic glands (Figure 6A ).
To determine whether 6 and 3 integrins were involved
in the same or in different adhesion complexes at the basal
membranes in the type I cancer phenotype ( i.e., cancers
expressing both subunits), we performed a comparison of
the two antigens in normal and in malignant prostate glands.
In the normal prostate gland, the 6 and 3 integrins were
strongly expressed in the basal membrane (Figure 7A ), but
were not found to be colocalizing when analyzed by high
resolution (not shown). In prostate cancer glands express-
ing both subunits ( type I ), 6 and 3 integrins were not
colocalized at the basal membranes (Figure 7;C  E ). At
high magnification, the 6 integrin staining could be
resolved from the 3 integrin staining at the basal
membrane (Figure 7C ), suggesting the existence of two
different cell - to-basal membrane adhesion sites and
complexes in prostate cancer glands.
Discussion
In this study, we have identified three prostate tumor
phenotypes expressing 6 and 3 integrins ( type I ), 6
integrin only ( type II ), or 3 integrin only ( type III ). Prostate
carcinoma is a heterogeneous disease with a wide spectrum
of pathologic and clinical manifestations. Most prostates with
cancer were shown to contain spatially and distinctly
separate tumors by the time of clinical diagnosis [36,37].
Multiple tumors from the same prostate were shown by in situ
hybridization and DNA analysis to be genetically different
and that even smaller tumors may give rise to distant lymph
node metastasis [2,3]. The demonstration of discordant
allelic deletion patterns on chromosomes 8p12-21 and
17q21 in distinctly separate tumors supported the hypothesis
of the independent origin of multiple tumors in prostate
cancer [3-5]. Our findings of the expression of different
prostate tumor phenotypes were consistent with these
previous observations showing the heterogeneity of prostate
tumors.
In contrast to the findings in the 4-negative PA-JEB skin
keratinocytes [11], we described in this study that the 6
integrin interestingly was not colocalized with vinculin or
paxillin in primary prostate carcinoma. Because paxillin is a
scaffold protein that provides docking sites for an array of
signaling and structural proteins and also provides linkage to
the actin cytoskeleton [38], these data suggest the existence
Figure 7. Confocal laser scanning micrographs of 6 (green; E ) and 3 integrin ( red; D ) in human normal (A ) and neoplastic prostate (Gleason grade 3+3,
pathological stage T3a; A–E ). (A ) Field with normal (N ) and cancer glands. Cancer gland 1 is shown at higher magnification in (B, D, and E). (C ) Shows high
resolution field of basal membrane in cancer gland 1. The monoclonal antibody specific for 3 integrin subunit showed some cross - reaction with the nuclei. N,
normal glands; V, vessel. Bars, 50 m (A ), 20 m (D), 2 m (C).
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of different cell–ECM adhesion complexes in prostate
tumors. Recently, cross linkers of the actin–filament
systems with plasma membrane receptors other than paxillin
have been described, such as the ERM (ezrin, radixin, and
moesin) proteins [39]. These newer members of the ERM
family were reported to play key roles in morphology, motility,
signal transduction, and apoptosis [40,41]. Furthermore, the
finding in type I tumors — that the 6 integrin was not
colocalized with the 3 integrin subunit — is consistent with
a recent study, which demonstrated a heterogeneity in the
composition of adhesion complexes [42]. It will be of great
interest to isolate by laser capture microscopy techniques
the proteins present within the 6-containing adhesion sites
in the tissue and determine their identity.
There is evidence that the morphology and molecular
composition of FAs are dependent on laminin isoforms and
on the integrins present in the complexes [43]. The
activation of the 61 integrin alone or the 61 with 31
integrin leads to the formation of different adhesion
complexes [43,44]. The formation of adhesion complexes
is crucial for signal transduction from the ECM into the cell
and vice versa [45,46]. Binding of integrins to extracellular
ligands leads to a series of events including clustering of
receptors, recruitment of FA linker proteins, actin polymer-
ization, and a phosphorylation cascade [46]. A different
ultrastructural arrangement of the molecules within the
adhesion complexes could be linked to the transmission of
different distinct signals. Consistent with this idea is our
observation that CD 151, a molecule laterally associated with
the 6 integrin, was present in prostate cancer, whereas
vinculin and paxillin were absent. Recently, CD 151 has been
implicated in novel signaling complexes inducing protein
kinase C [47].
The association of the integrin expression with the
Gleason sum score was consistent with the fact that many
human carcinomas have a decreased expression of integrins
when compared with normal tissue [22]. However, for
human pancreatic carcinoma, no correlation of integrin
expression with tumor differentiation was observed [48].
Interestingly, 44% of the prostate tumors with a Gleason sum
score7 expressed either one of the described phenotypes.
However, in differentiated tumors (Gleason sum score 6)
invading into the seminal vesicles (pathological stage T3c),
only the phenotypes I (6 +3 integrin) and II (6 integrin
only) with high expression levels of the 6 subunit were
observed. This suggests that the clustered expression of 6
integrin may be correlated with invasion and the failure to
express 3 integrin may be related to more aggressive
tumors (T3c). There is evidence that the interaction of 31
with the adjacent basal membrane might transduce signals
that inhibit the invasive behavior of epithelial cells [49,50],
although its functional role is still poorly understood. In
contrast, a role for the 61 integrin in invasion was
suggested by previous studies [23,51,52]. Recently, the
existence of a new subtype of 6 integrin lacking the
extracellular ‘‘beta-barrel’’ domain was demonstrated in
various cell types and was upregulated in cancer cells that
exhibited migratory-enhancing properties [53]. This study
also showed that the 6-specific antibody (GoH3) used
here will not distinguish between the two 6 integrin forms
[53]. Therefore, a switch between the 6 integrin subtypes
from normal to cancer may have occurred. This is the subject
of further study to determine the distribution of this novel
structural variant within the three phenotypes.
The invasive potential of the tumor phenotypes express-
ing different adhesion complexes may also be determined
by the availability or composition of their extracellular
ligands. Laminins 5, 10, and 11 were shown to be preferred
ligands for 31 [54]. The 61 integrin also was reported
to be a major receptor for laminin 10/11 in human
pancreatic carcinoma cells [55] and mouse hematopoietic
cells [56]. A recent study showed that fibroblast adhesion to
laminin 10/11 was mediated by both 31 and 61
integrins [57]. It will be of interest to determine the
composition and localization of the different laminin forms
within the three different integrin tumor phenotypes. Under-
standing the factors contributing to the invasive potential of
prostate carcinoma is of fundamental importance in this
disease.
Prostate cancer is unique in that latent and aggressive
phenotypes exist. Currently used prognostic factors for the
management of the disease include the histopathological
evaluation of tumor size, grade, and localization and
distribution within the gland [58]. For example, if invasion
to the seminal vesicle had occurred, the disease- free 10-
year survival rate in patients decreased by approximately
50% as compared to the one in patients without seminal
vesicle invasion [59]. Other studies showed that prostate
cancers with established capsular penetration had a higher
risk of progression than those with focal capsular penetration
[60]. Capsular penetration is correlated with lymph node
metastasis [61]. The preferred sites of metastasis in prostate
cancer are lymph nodes and bone marrow — sites enriched
with laminin 10/11 [62]. Taken together, these data suggest
that retention of laminin 10/11 receptors by the cancer cells
may play a role in prostate cancer metastasis.
The further understanding of integrin laminin receptors
and the different integrin-containing adhesion phenotypes
will contribute to determining their role in prostate cancer
metastasis. We propose that the three tumor phenotypes,
which are distinguished by differential integrin expression,
will be useful for the separation of cases with organ-confined
disease from cases with capsular penetration or with seminal
vesicle invasion.
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